Optimizing and Successful Treatment of Infliximab for Patients with Crohn's Disease―in Terms of Maintenance of Mucosal Healing Satoshi Motoya 1 , Hiroki Tanaka 2 , Suguru Nakagaki 2 , Masanao Nasuno 2 , Akimichi Imamura 2 , Tomonori Anbo 2 , Sei Kurokawa 2 , Hiroshi Kozawa 2 , Satoshi Maeda 2 , Takeshi Hagiwara 2 , Hitoshi Nisioka 2 , Masayuki Nakanowatari 2 1First Department of Gastroenterology, Sapporo-Kosei General Hospital, Sapporo, Japan 2First Department of Internal Medicine, School of Medicine, Sapporo Medical University, Sapporo, Japan Keyword: 抗TNF-α抗体 , infliximab , Crohn病 , 粘膜治癒 , 計画的維持投与 pp.1832-1842
Published Date 2007/12/25
DOI https://doi.org/10.11477/mf.1403101238
  • Abstract
  • Look Inside
  • Reference

 We investigated mucosal healing rate and rehospitalization rate for patients with Crohn's disease (CD) who underwent scheduled maintenance infusion of infliximab. Scheduled maintenance infusion improved healing rate to 43.5% after 1 year, 64.7% after 2 years, 70.0% after 3 years respectively, in spite of there being initially only a 21.4% healing rate without this scheduled infusion of infliximab. It seemed that continuous regulation of TNF-αled to mucosal healing of active longitudinal ulcers caused by CD. Also, it significantly improved rehospitalization rate compared with that of conventional therapy such as elemental nutrition and immuno-modulators including episodic infusion of infliximab. These results shows scheduled maintenance infusion every 8 weeks following triple initial infusion of infliximab has been an optimizing and successful procedure enabling the maintenance of long-term remission of CD.

Copyright © 2007, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院